CGRP's effect on hearing and balance in a mouse model of migraine
CGRP 对偏头痛小鼠模型听力和平衡的影响
基本信息
- 批准号:10174909
- 负责人:
- 金额:$ 32.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAuditory systemBlocking AntibodiesCalcitonin Gene-Related PeptideCalcitonin-Gene Related Peptide ReceptorCannulasCerebrospinal FluidChronicClinicClinicalClinical TrialsCochlear NerveControl GroupsDevelopmentDizzinessEquilibriumExhibitsFemaleFiberFutureGoalsHeadacheHearingHomologous GeneHypersensitivityImpairmentImplantInfusion proceduresInjectionsIntraperitoneal InjectionsLabyrinthLightMeasuresMigraineMotion SicknessMusNauseaNeuronsNeuropeptidesPatientsPerformancePeripheralPharmaceutical PreparationsPhonophobiasPhotophobiaPhotosensitivityPopulationPosturePre-Clinical ModelPredispositionRAMP1RecoveryRecurrenceRouteSalineSensorySerotoninSignal TransductionSymptomsTestingTherapeuticTransgenic MiceVentricularVertigoWild Type Mousebaseeffective therapyexperienceintraperitonealmouse modelnervous system disordernestin proteinnovel therapeuticsotoconiapeptide Ireceptorresponsesoundtranslational studytriptansvestibulo-ocular reflex
项目摘要
Migraine is a severe and chronic neurological disorder that affects ~18% of people worldwide, majority
female (3:1). Migraine is characterized by recurrent attacks of debilitating headaches and nausea, with
heightened sensory sensitivities, such as light (photophobia) and sound (phonophobia). Recently it has
become recognized that ~42% of migraine patients also suffer from balance problems and dizziness, termed
vestibular migraine (VM). VM is a major cause of vertigo in dizziness clinics, and is estimated to affect 1% of
the overall population. Clinically, triptans (serotonin 5-HT 1B/1D receptor agonists) can reduce photophobia
and headaches in migraine, but often do not relieve other VM symptoms. Thus, there is an urgent need for
validated preclinical models for VM.
The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a key player in migraine based
on the efficacy of CGRP blockers in clinical trials against headache, and injection of CGRP triggers migraine.
We have developed CGRP-sensitized transgenic mouse models for migraine that have heightened responses
to light (photophobia) when CGRP is delivered either centrally or systemically. We have shown that CGRP
blockers can block CGRP-induced photosensitivity in these mice, yet CGRP blockers delivered systemically
cannot effectively penetrate the CNS, and these blockers are not effective against centrally-induced
photophobia, suggesting that photosensitivity in migraine involves both systemic and central components.
CGRP is also widely distributed throughout the vestibular CNS, and CGRP-containing efferent fibers project to
all inner ear endorgans. CGRP is also signaling in the vestibular and auditory systems, as we discovered in a
different mouse model, that the loss of CGRP reduces the vestibulo-ocular reflex (VOR) gain, reduces otolith-
evoked dynamics reduces, reduces sound-evoked activity in the cochlear nerve, and impairs rotarod (balance)
performance. Yet, it is not yet known if CGRP is acting centrally or peripherally in VM; which would influence
treatment routes and efficacy. We propose to measure mouse homologues of clinical VM symptoms namely;
phonophobia, imbalance, nausea, and motion-sickness susceptibility; and will investigate these measures in
three mouse lines: i) wildtype (WT) littermate controls and CGRP-sensitized mouse models with ii) neuronally-
sensitized CGRP receptors (nestinRAMP1) or iii) globally-sensitized CGRP receptors (global RAMP1). Our
hypothesis is that elevated CGRP-sensitivity will contribute to increased sensitivities found in VM; and
that these VM symptoms will be ameliorated by CGRP blockers.
Information gained from these studies will provide a direct assessment of whether CGRP-sensitized mouse
models that have been shown to mirror the photophobia of migraine, can also mirror deficits observed in VM.
Such a preclinical model of VM could be used for future translational studies to develop and test new
therapeutics. !
偏头痛是一种严重的慢性神经系统疾病,影响全世界约18%的人
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE E LUEBKE其他文献
ANNE E LUEBKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE E LUEBKE', 18)}}的其他基金
Effects of music training on auditory processing and high-frequency hearing abilities in adolescent musicians
音乐训练对青少年音乐家听觉处理和高频听力能力的影响
- 批准号:
10017174 - 财政年份:2019
- 资助金额:
$ 32.7万 - 项目类别:
CGRP's effect on hearing and balance in a mouse model of migraine
CGRP 对偏头痛小鼠模型听力和平衡的影响
- 批准号:
10434800 - 财政年份:2018
- 资助金额:
$ 32.7万 - 项目类别:
Early auditory and imbalance measures in a mouse model of Alzheimer's Disease-Supplement
阿尔茨海默病小鼠模型的早期听觉和不平衡测量-补充剂
- 批准号:
10283003 - 财政年份:2018
- 资助金额:
$ 32.7万 - 项目类别:
Administrative Supplement to CGRP's effect on hearing and balance in a mouse model of migraine
CGRP 对偏头痛小鼠模型听力和平衡影响的行政补充
- 批准号:
10173048 - 财政年份:2018
- 资助金额:
$ 32.7万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 32.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 32.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 32.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




